About 11% of US adults currently take a GLP-1 weight loss medication — roughly 28 million people. Another 15% say they’ve tried one at some point. That’s a number that has nearly quadrupled since 2024, when only 3% of adults reported current use. And by most projections, it’s still far short of where the market is headed.
These aren’t estimates or model projections. The 11% figure comes from a Gallup survey of 5,065 US adults conducted June 2026, the most authoritative measure of real-world prevalence available. The numbers are moving fast enough that whatever was true 18 months ago has likely been overtaken.
Key takeaways
- 11% of US adults currently take a GLP-1 drug for weight loss (Gallup, June 2026) — up from 3% in 2024.
- 15% of US adults have used one at some point — a nine percentage point jump from 2025.
- 91% of US adults are now aware of GLP-1 weight loss drugs, up from 80% two years ago.
- 37% of Americans say a close friend or family member currently uses one.
- Only 1 in 10 people who clinically qualify are actually taking a GLP-1 drug, per Eli Lilly’s CEO.
- 57.4 million privately insured US adults meet the clinical criteria — but only a fraction have a prescription.
- GLP-1 prescriptions for weight loss grew 587% between 2019 and 2024, per FAIR Health data.
- The US adult obesity rate has fallen to 36.4% in 2026 — down from a peak of 39.9% in 2022.
The current number: 28 million Americans
The simplest answer to the question is this: approximately 28 million US adults currently take a GLP-1 receptor agonist for weight loss as of mid-2026. That figure scales from the Gallup 11% finding against the US adult population of about 260 million.
It’s the highest adoption rate ever recorded for a prescription weight loss drug category in US history.
A separate KFF (Kaiser Family Foundation) poll, which counted GLP-1 use across all indications — weight loss, diabetes, and cardiovascular disease together — found roughly 1 in 8 US adults currently taking one. That broader figure is consistent with the Gallup weight-loss-specific number once diabetes-only use is added.
The two surveys together paint a clear picture: somewhere between 28 and 35 million Americans currently use a GLP-1 drug for any reason.
How fast the numbers grew
The growth rate is arguably as striking as the current number. GLP-1 use for weight loss specifically grew 587% between 2019 and 2024, according to a FAIR Health analysis of over 51 billion commercial healthcare claims records.
The pace has continued accelerating:
| Year | US adults currently using GLP-1 for weight loss |
|---|---|
| 2019 | ~0.9% |
| 2021 | ~1.5% (Wegovy FDA approved) |
| 2022 | ~2.5% |
| 2024 | ~3–5.8% |
| 2026 (Gallup, June) | 11% |
That’s not linear growth. It’s exponential adoption driven by three overlapping forces: new drug approvals that produce dramatically better results, expanded insurance and government coverage, and the Wegovy pill launching January 2026 and reaching patients who had avoided injectable GLP-1s.
By the end of the decade, JP Morgan projects up to 30 million Americans on GLP-1 medications — a number the 2026 data suggests may be reached sooner than that timeline implied when it was written.
Who is using weight loss drugs
The profile of the typical GLP-1 user has shifted meaningfully since 2022.
- By age: Adults aged 40–59 account for the largest share of GLP-1 weight loss prescriptions. Use among those under 40 is growing fastest. Adults over 65 report lower effectiveness and are less likely to be on GLP-1s for weight loss, though Medicare coverage through the GLP-1 Bridge program launched July 1, 2026 is opening the door.
- By gender: Women account for approximately 60–65% of GLP-1 weight loss users. The gap is driven by a combination of higher baseline rates of seeking weight management care and the overlap with conditions like PCOS and perimenopause, where GLP-1 use is increasingly relevant.
- By condition: About 70% of GLP-1 users take the drug at least partly for a chronic condition — type 2 diabetes, cardiovascular disease, or a weight-related comorbidity — rather than weight loss alone. The pure weight-loss-only segment is the fastest-growing but not yet the majority.
- By awareness: 91% of US adults are now aware of GLP-1 drugs. That’s near-saturation awareness, typically associated with mainstream categories like statins or blood pressure medications — not emerging drug classes. The barrier is no longer awareness. It’s access and cost.
The enormous gap between who qualifies and who gets access
The most striking number in the 2026 landscape isn’t how many people are using these drugs. It’s how many are eligible but aren’t.
57.4 million privately insured US adults meet the clinical criteria for a GLP-1 prescription — a BMI of 30 or higher, or BMI 27+ with a qualifying comorbidity. That’s 42% of all adults with private health insurance.
Of those, only a small fraction — estimated around 3–10% — had a GLP-1 prescription at the time most of these analyses were conducted. Even at 11% current use, the penetration rate against the eligible population is somewhere around 15–20%.
Eli Lilly CEO David Ricks put it plainly in April 2026: fewer than 1 in 10 people who could benefit from a GLP-1 are taking one.
The constraint isn’t demand or awareness. It’s two things: cost and coverage. Despite improving, insurance coverage for weight-loss GLP-1s remains incomplete. As of mid-2026:
- Only 43% of large employers (5,000+ workers) cover GLP-1s for obesity — up from 28%, but still a minority
- 27 million people lack any commercial insurance coverage for Wegovy specifically
- Medicare only began covering weight-loss GLP-1s on July 1, 2026 through the GLP-1 Bridge program
Each coverage expansion produces a wave of new prescriptions. The July 2026 Medicare Bridge is expected to bring millions of previously ineligible patients into the market before the end of 2026.
Which drugs Americans are actually taking
Tirzepatide — sold as Mounjaro for diabetes and Zepbound for weight loss — overtook semaglutide as the most-prescribed GLP-1 molecule in the US by early 2026. By Q1 2026, tirzepatide ran at roughly 4,700 prescriptions per 100,000 adults versus 3,900 for semaglutide.
That comparison reflects total prescriptions across indications. Within the weight loss segment specifically, Wegovy commands about 65% of new GLP-1 weight-loss prescriptions as of mid-2026.
The Wegovy pill deserves its own note. Launched January 5, 2026, it passed 3 million prescriptions faster than any GLP-1 in history. It’s attracting a meaningfully different patient — people who had been aware of and eligible for GLP-1 therapy but unwilling to take weekly injections. Oral GLP-1s are genuinely expanding the user base rather than just shifting it.
For a full picture of brand-level market share, see semaglutide in 2026 usage guide.
What this is doing to obesity rates
The population-level effect is becoming visible. After peaking at 39.9% in 2022 — the year after Wegovy’s FDA approval — the US adult obesity rate has fallen to 36.4% in 2026, according to Gallup’s tracking data. That’s the first sustained multi-year decline in modern tracking history.
The diabetes trend is telling too. Diabetes diagnosis rates, which had risen slowly for 15 years in line with rising obesity, have now plateaued. They haven’t reversed yet — diabetes is a lifetime diagnosis — but the rate of new diagnoses is stabilizing.
Researchers have attributed both trends directly to GLP-1 adoption. The math is plausible: if 28 million people are losing 10–20% of their body weight, the downstream effects on obesity-related disease rates would be expected to show up with a 2–4 year lag. That lag is roughly what we’re observing.
This is likely the beginning of the population-level signal, not the peak of it.
Where the numbers are heading
The trajectory depends on three variables: coverage, price, and the drug pipeline.
- Coverage is expanding. The Medicare GLP-1 Bridge (July 2026) is the single biggest access event in the drug’s history. Medicaid coverage is growing state by state. Employer coverage is increasing but still below 50%.
- Price is declining for many patients. TrumpRx pricing capped Ozempic, Wegovy, Mounjaro, and Zepbound at $245/month for qualifying buyers. LillyDirect self-pay vials start at $299/month. The Wegovy pill starts at $149/month. Foundayo (orforglipron), the newest oral GLP-1, launched at $149/month too.
- The drug pipeline keeps raising the ceiling. Retatrutide — which produced 28.3% average weight loss in Phase 3 trials — has an NDA filing expected in Q4 2026. When drugs that effective become available, adoption accelerates.
JP Morgan’s projection of 30 million Americans on GLP-1s by end of decade was written when only 3–4% of adults were taking them. At 11% and rising, that number may be crossed by 2028 rather than 2030.
Conclusion
The numbers tell a straightforward story: more Americans are using weight loss drugs than ever before, the growth is accelerating rather than plateauing, and the gap between who could benefit and who currently does remains enormous.
11% of US adults on GLP-1s for weight loss is a record high. It’s also probably a floor. Coverage is expanding, prices are falling, oral options are removing the injection barrier, and a new wave of drugs is coming that will raise the ceiling on what weight loss medication can do.
The more revealing number might be the one Eli Lilly’s CEO offered: fewer than 1 in 10 people who could benefit are currently taking these drugs. The story of GLP-1 adoption in America is less than halfway written.
If you’re one of the people who qualifies but hasn’t yet started, book a free consultation with Heally to explore your options with a licensed provider — same-day telehealth appointments available in 40+ states, prescription delivered to your door.
FAQ
How many Americans are taking weight loss drugs in 2026?
About 11% of US adults — approximately 28 million people — currently take a GLP-1 weight loss drug, according to a Gallup survey conducted June 2026. Another 15% report having tried one at some point.
What percentage of Americans have used GLP-1 drugs?
15% of US adults have used a GLP-1 medication for weight loss at some point, up nine percentage points from 2025. 11% are currently using one. A broader measure counting all GLP-1 uses (including diabetes) puts current use at about 1 in 8 adults.
How fast is GLP-1 use growing?
Very fast. Prescriptions for GLP-1 weight loss drugs grew 587% between 2019 and 2024. Current use tripled from 3% to 11% of US adults between 2024 and 2026 alone — in two years.
Who qualifies for weight loss drugs?
Adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition (type 2 diabetes, hypertension, cardiovascular disease, obstructive sleep apnea). 57.4 million privately insured US adults meet these criteria — about 42% of adults with private insurance.
Why aren’t more people using weight loss drugs if so many qualify?
Cost and coverage are the main barriers. Despite improving, only 43% of large employers cover GLP-1s for obesity. Many commercial plans still don’t cover them for weight loss. Medicare only began covering them for weight loss on July 1, 2026. Even those who can access them sometimes find the out-of-pocket cost prohibitive.
Are weight loss drugs actually reducing obesity in the US?
The data suggests yes. US adult obesity rates fell from a peak of 39.9% in 2022 to 36.4% in 2026 — the first sustained multi-year decline ever tracked. Researchers have attributed this directly to GLP-1 adoption.
How many Americans will use weight loss drugs by 2030?
JP Morgan projected up to 30 million Americans on GLP-1 drugs by end of decade when 3–4% were using them. At 11% and rising, that projection may be reached by 2028. The actual number depends on how fast coverage expands and how new drugs like retatrutide accelerate adoption.
Related reading on Heally:
- How weight loss actually works: calories, metabolism, and hormones
- 5 GLP-1 trends to expect in 2026: expanded uses, oral options, and more
- Is Ozempic becoming yesterday’s weight loss drug?
- Tirzepatide vs semaglutide: key differences and weight loss results
Sources
- Gallup — In US, GLP-1 usage reaches new high (July 2026)
- KFF — 1 in 8 adults currently taking a GLP-1 drug for weight loss, diabetes, or another condition
- FAIR Health — Use of GLP-1 drugs to treat overweight or obesity increased 587% from 2019 to 2024
- Pabau — 65 GLP-1 statistics for 2026 (every figure sourced)
- GoalBMI / Forbes Health — GLP-1 weight loss statistics 2026: semaglutide and tirzepatide data
- Peterson-KFF Health System Tracker — Perspectives from employers on covering GLP-1 agonists for weight loss (2026)
- JP Morgan — How demand for and supply of weight loss drugs is playing out in 2026
- WHO — WHO issues global guideline on the use of GLP-1 medicines in treating obesity (2026)
Data disclaimer: Statistics in this article reflect surveys and market data available as of July 2026. GLP-1 adoption is growing rapidly — check primary sources for the most current figures.